October 16, 2020 – Dan Hargrave was struggling to breathe, and he and his physicians initially were not sure why. He had asthma as a child, but his doctors were not confident this was the cause. Eventually, Dan was diagnosed with chronic obstructive pulmonary disease (COPD). He did not know it at the time, but the 340B drug pricing program would be a key element of how he would … [Read more...]
Drug Industry Report on 340B Attempts a Diversion from Unlawful Manufacturer Actions
October 14, 2020— A new report from the drug industry consultant Berkeley Research Group (BRG) takes aim at community-based pharmacies in the 340B drug pricing program. The report implies, without evidence, that for-profit pharmacy chains are making excessive profits on these arrangements. It ignores the fact that these partnerships provide critical funding for safety-net and … [Read more...]
340B Hospitals Support Mental Health Challenges No Matter the Circumstances
October 9, 2020 – Fifty percent. According to the Centers for Disease Control and Prevention (CDC), this is the estimated percentage of Americans who will be diagnosed with a mental illness or disorder in their lifetime. Prior to the COVID-19 pandemic, mental health already was one of the top health challenges Americans faced. But as we recognize National Mental Illness … [Read more...]
We Have More Reasons Than Ever to Celebrate Pharmacists This Month
October 7, 2020— October is American Pharmacists Month, and this year we have even more reasons to celebrate their contributions to the health care system. Pharmacists are as essential to the health care system’s mobilization in the face of the current public health crisis as the emergency room physicians, the epidemiologists, the intensive care unit nursing staff, and others … [Read more...]
JAMA Study Shows 340B Can Help Restrain Drug Price Hikes
September 22, 2020— A recent Wall Street Journal opinion piece by a pharmaceutical industry consultant resurfaces claims that statutory discounts for safety-net hospitals, health centers, and clinics are forcing drug companies to hike their prices. Drug manufacturers are using this false notion as a pretext for urging program cutbacks in the guise of “reforms” and for refusing … [Read more...]
Outcry Intensifies Over Pharma Moves Against 340B
September 10, 2020— Five major pharmaceutical companies are flouting the 340B drug pricing program statute, and others appear poised to follow suit. But a vocal group of safety-net providers and national organizations are calling on the federal government to use its authority to put a stop to those actions before patients are harmed. Beginning in late June, the drug makers … [Read more...]
340B Experts Navigate in a World Turned Upside Down
By Maureen Testoni August 13, 2020 - In “Hamilton” – my favorite musical – performers describe Revolutionary-era America as “a world turned upside down.” For many of us who work to support the health care safety net in the U.S., that feels like a very apt description of our current environment. A worldwide pandemic coupled with a historic economic decline has changed the … [Read more...]